Nathan Standifer
Tempest Technologies (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cancer, Hypoxia, and Metabolism, Cytokine Signaling Pathways and Interactions, Peroxisome Proliferator-Activated Receptors
Most-Cited Works
- → Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases(2006)527 cited
- → Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study(2021)430 cited
- → Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia(2018)240 cited
- → Recurrence of Type 1 Diabetes After Simultaneous Pancreas-Kidney Transplantation, Despite Immunosuppression, Is Associated With Autoantibodies and Pathogenic Autoreactive CD4 T-Cells(2010)209 cited
- → ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors(2011)139 cited
- → Recognition of HLA Class I–Restricted β-Cell Epitopes in Type 1 Diabetes(2006)103 cited
- → Assessment of Seasonal Influenza A Virus-Specific CD4 T-Cell Responses to 2009 Pandemic H1N1 Swine-Origin Influenza A Virus(2010)101 cited
- → Identification of Novel HLA-A*0201–Restricted Epitopes in Recent-Onset Type 1 Diabetic Subjects and Antibody-Positive Relatives(2006)91 cited
- → Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown(2021)80 cited
- → Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development(2015)58 cited